Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea B Apolo

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Clinical Genitourinary Cancer|October 6, 2018
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary CarcinomaPavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Med (New York, N.Y.)|December 13, 2022
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeGal Dinstag, Eldad D Shulman, Efrat Elis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
The Lancet. Oncology|July 10, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trialAndrea B Apolo, Rosa Nadal, Yusuke Tomita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Clinical Genitourinary Cancer|October 6, 2018
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary CarcinomaPavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Med (New York, N.Y.)|December 13, 2022
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeGal Dinstag, Eldad D Shulman, Efrat Elis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
The Lancet. Oncology|July 10, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trialAndrea B Apolo, Rosa Nadal, Yusuke Tomita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Pageof 12